WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of ...
Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indications Management ...
WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results